TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
EHE Foundation
We are thrilled to share a new publication, “EHE cell cultures are a platform for mechanistic and therapeutic investigation,” made possible by a partnership between the University of Iowa and the EHE Foundation. Under the leadership of Dr. Munir Tanas, Nicholas Scalora, PhD, and colleagues in the Tanas Lab sought to develop long-term EHE cell […]
FOR IMMEDIATE RELEASE Hobart, WI – October 9, 2025 – The Center for Research and Analysis of VAscular Tumors (CRAVAT) Foundation has donated its resources to The EHE Foundation in a powerful alignment of vision and commitment to the people affected by epithelioid hemangioendothelioma (EHE) and the EHE scientific community. Founded in 2015 by Guy […]
On Saturday, June 28, 2025, more than 80 golfers, friends, and family gathered at Stony Creek Golf Course in Oak Lawn, Illinois, for the Third Annual Big Steve Day Golf Outing — a day filled with laughter, camaraderie, and purpose. This annual event honors the life and spirit of Steve Walsh, Jr., whose memory continues […]
A project funded by the EHE Foundation, the EHE Rare Cancer Charity (UK), and the EHE Rare Cancer Foundation Australia, and led by Dr. Ryan Kanai in the Lamar Lab, was recently published in Cancers, revealing a surprising new role for AMPK in controlling the growth of EHE cells. Dr. Kanai set out to find […]
We are thrilled to share a new publication that includes participation of EHE advocacy organizations: “How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.” Leaders of the EHE Rare Cancer Charity (UK), the EHE Foundation, and EHE ITALIA Associazione Non Solo Laura […]
In 2022, the EHE Foundation funded the Lamar Lab’s project entitled ‘Use of Pre-clinical EHE Models to Identify Druggable Pathways to Treat EHE,’ with the goal of identifying FDA-approved drugs that can be repurposed to treat EHE. By looking for drugs that are already FDA-approved, ideally, positive pre-clinical findings could be more rapidly translated to […]